ClinicalTrials.gg

Program

lisdexamfetamine

Also written as “SPD489”, “NRP104” and “SPD489 (Lisdexamfetamine dimesylate)”.

Its studies are mostly in Attention Deficit Disorder with Hyperactivity · Schizophrenia · Depressive Disorder, Major · Binge-Eating Disorder · Sleep Deprivation, led by 3 companies.

Furthest: phase 4, since Jul 10, 200747 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda450 open or runningphase 4since Jul 10, 2007Oct 31, 2005none ahead
Humanis Saglık Anonim Sirketi10 open or runningphase 1since Jul 25, 2025Jul 25, 2025none ahead
Knoa Pharma10 open or runningphase 3since Aug 28, 2015Aug 28, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 30 studies since Oct 31, 2005.

  1. Sep 15, 2011Phase 2 study in Depressive Disorder, MajorTakeda · NCT01435759 · 1,197 enrolled · United States, Argentina, Australia and more
  2. Oct 19, 2011Phase 1 study in SchizophreniaTakeda · NCT01457339 · 31 enrolled · United States
  3. Mar 6, 20122 phase 4 studies in Attention Deficit Disorder with HyperactivityTakeda · NCT01552915, NCT01552902
  4. Aug 1, 2012Phase 3 study in Binge-Eating DisorderTakeda · NCT01657019 · 604 enrolled · United States, Germany, Spain
  5. Oct 29, 20122 phase 3 studies in Binge-Eating DisorderTakeda · NCT01718509, NCT01718483
  6. Nov 28, 2012Phase 3 study in SchizophreniaTakeda · NCT01738698 · 4 enrolled · United States
  7. Jan 2, 20132 phase 3 studies in SchizophreniaTakeda · NCT01760993, NCT01760889
  8. Jun 27, 2013Phase 1 study in Healthy VolunteersTakeda · NCT01890785 · 30 enrolled · United States
  9. Dec 6, 2013Phase 3 study in Binge-Eating DisorderTakeda · NCT02009163 · 418 enrolled · United States, Canada, Germany and more
  10. Mar 19, 2015Phase 2 study in Attention Deficit Disorder with HyperactivityTakeda · NCT02402166 · 24 enrolled · United States
  11. Jun 4, 2015Phase 3 study in Attention Deficit Disorder with HyperactivityTakeda · NCT02466386 · 113 enrolled · United States
  12. Aug 28, 2015Knoa Pharma's first study: phase 3 study in Attention Deficit Disorder with HyperactivityNew to Knoa PharmaKnoa Pharma · NCT02555150 · 40 enrolled · United States
  13. Aug 9, 2017Phase 3 study in Attention Deficit Disorder with HyperactivityTakeda · NCT03260205 · 199 enrolled · United States
  14. Jul 25, 2025Humanis Saglık Anonim Sirketi's first study: phase 1 study in Attention Deficit Disorder with HyperactivityNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT07098585 · 48 enrolled · India

TargetBeta

“Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor”ChEMBL 37, by rule

Studies

All 47 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07098585Attention Deficit Disorder with Hyperactivity · India1CompletedHumanis Saglık Anonim SirketiJun 6, 202548
NCT03260205Attention Deficit Disorder with Hyperactivity · United States3CompletedTakedaOct 23, 2018199
NCT02555150Attention Deficit Disorder with Hyperactivity · United States3CompletedKnoa PharmaJan 201740
NCT02466386Attention Deficit Disorder with Hyperactivity · United States3CompletedTakedaJan 3, 2020113
NCT02402166Attention Deficit Disorder with Hyperactivity · United States2CompletedTakedaJun 30, 201624
NCT02009163Binge-Eating Disorder · United States, Canada, Germany and more3CompletedTakedaApr 8, 2015418
NCT01890785Healthy Volunteers · United States1CompletedTakedaAug 22, 201330
NCT01760993Schizophrenia · United States3TerminatedTakedaApr 1, 20132
NCT01760889Schizophrenia · United States3TerminatedTakedaApr 1, 20131
NCT01738698Schizophrenia · United States3TerminatedTakedaApr 1, 20134
NCT01718509Binge-Eating Disorder · United States, Germany3CompletedTakedaSep 20, 2013390
NCT01718483Binge-Eating Disorder · United States, Germany, Spain and more3CompletedTakedaSep 25, 2013383
NCT01657019Binge-Eating Disorder · United States, Germany, Spain3CompletedTakedaOct 21, 2014604
NCT01552915Attention Deficit Disorder with Hyperactivity · United States4CompletedTakedaJan 22, 2014464
NCT01552902Attention Deficit Disorder with Hyperactivity · United States, Canada, Germany and more4CompletedTakedaMay 22, 2014549
NCT01457339Schizophrenia · United States1CompletedTakedaJan 20, 201231
NCT01436175Depressive Disorder, Major · United States, Canada, Chile and more3TerminatedTakedaMar 27, 20141,570
NCT01436162Depressive Disorder, Major · United States, Belgium, Czechia and more3CompletedTakedaDec 10, 20131,105
NCT01436149Depressive Disorder, Major · United States, Canada, Croatia and more3CompletedTakedaDec 23, 20131,262
NCT01435759Depressive Disorder, Major · United States, Argentina, Australia and more2CompletedTakedaJan 17, 20141,197
NCT01328756Attention Deficit Disorder with Hyperactivity · Belgium, Germany, Hungary and more4CompletedTakedaSep 30, 2014314
NCT01291173Binge-Eating Disorder · United States2CompletedTakedaJan 30, 2012271
NCT01274221Attention Deficit Disorder with Hyperactivity · United States3WithdrawnTakedaMay 4, 20110
NCT01234298Negative Symptoms of Schizophrenia3WithdrawnTakedaFeb 24, 20140
NCT01106430Attention Deficit Disorder with Hyperactivity · United States, Belgium, Canada and more3CompletedTakedaJul 19, 2012267
NCT01101022ADHD Specifically With Executive Function Impairment · United States4CompletedTakedaNov 29, 2010161
NCT01096680Sleep Deprivation · United States2CompletedTakedaJul 18, 2010135
NCT01010750Attention Deficit Disorder with Hyperactivity · United States1CompletedTakedaMar 28, 201018
NCT00985725Depressive Disorder, Major · United States2CompletedTakedaApr 18, 2011143
NCT00922272Schizophrenia · United States2CompletedTakedaJan 20, 201192
NCT00919867Healthy · United States1CompletedTakedaJul 30, 200942
NCT00905424Depressive Disorder, Major · United States2CompletedTakedaAug 4, 2010246
NCT00877487Attention Deficit Disorder with Hyperactivity · United States4CompletedTakedaJul 8, 2010123
NCT00784654Attention Deficit Disorder with Hyperactivity · United States, Belgium, France and more3CompletedTakedaOct 26, 2011276
NCT00776555Healthy · United States1TerminatedTakedaMar 31, 20093
NCT00763971Attention Deficit Disorder with Hyperactivity · Belgium, France, Germany and more3CompletedTakedaMar 16, 2011336
NCT00764868Attention Deficit Disorder with Hyperactivity · United States3CompletedTakedaApr 22, 2010269
NCT00746733Healthy Volunteers · United States1CompletedTakedaOct 26, 200824
NCT00735371Attention Deficit Disorder with Hyperactivity · United States3CompletedTakedaApr 6, 2009314
NCT00557011Attention Deficit Disorder with Hyperactivity2CompletedTakeda52
NCT00556296Attention Deficit Disorder with Hyperactivity3CompletedTakeda297
NCT00500149Attention Deficit Disorder with Hyperactivity · United States3CompletedTakedaDec 5, 2007129
NCT00500071Attention Deficit Disorder with Hyperactivity · United States4CompletedTakedaJan 2, 2008318
NCT00337285Attention Deficit Disorder with Hyperactivity · United States3CompletedTakedaNov 2007349
NCT00334880Attention Deficit Disorder with Hyperactivity · United States3CompletedTakeda420
NCT00248092Attention Deficit Disorder with Hyperactivity · United States2CompletedTakeda36
NCT00247572Attention Deficit Disorder with Hyperactivity · United States2CompletedTakeda12

How it is read

Names in the registry

  • “SPD489”, 6 entries
  • “NRP104”, 6 entries
  • “SPD489 (Lisdexamfetamine dimesylate)”, 5 entries
  • “Lisdexamfetamine dimesylate”, 5 entries
  • “Lisdexamfetamine Dimesylate”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.